Trial Profile
A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Semzuvolimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors United BioPharma
- 18 Apr 2019 Results published in the New England Journal of Medicine
- 17 Apr 2019 According to an United BioPharma media release, results of the study were published in The New England Journal of Medicine (NEJM).
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections